That decision was taken, but when it was taken in terms of allowing OxyContin to remain on the market—and having allowed it on the market, if there are generic versions available it's very hard to deny them—at that time a number of stronger restrictions were put in place in terms of the licensing for reporting, for diversions, and so forth. We have been monitoring that very closely. From that monitoring we haven't seen any spike or increases yet.
But as the minister has said I think on a number of occasions, it is a significant concern. That's why there's going to be significant additional investment in dealing with prescription drug abuse. I would say the minister has also indicated that an important component of this is to look at options for tamper resistance that would also be a factor in helping.